Valentina Hernández-Santamaría
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Valentina Hernández-Santamaría has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Adwar Peña Peña
Internal Medicine, Cardioinfantil Foundation-Cardiology Institute, Bogotá, Colombia
1 shared publication - David Corredor-Orlandelli
School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
1 shared publication - Juan Felipe Aguirre-Ruiz
Internal Medicine Department Fundación Cardioinfantil—LaCardio, Bogotá 110111, Colombia
1 shared publication - Laura Valenzuela-Vallejo
School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
1 shared publication - Sergio Alzate-Ricaurte
School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 110111, Colombia
1 shared publication
Latest Publications
- Open Access
- 26 November 2021
- Published by MDPI AG in Clinics and Practice
- Vol. 11 (4) , 914-918
Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report
Coronavirus 19 disease (COVID-19) presents a highly variable clinical presentation and course, ranging from asymptomatic patients to rapidly progressive, fatal pneumonia. The known heterogeneous outcomes can affect both previously healthy patients and those with significant comorbidities, who develop clinical courses with possibly more multisystemic compromise. Likewise, the development of thrombotic phenomena during the acute course of the disease is associated with complications that worsen patient prognosis. We present a case report of a 45-year-old multiparous patient with a history of overweight and chronic use of oral hormonal contraception with low doses of levonorgestrel and estradiol as the only risk factors favoring the development of thrombotic events. During her outpatient COVID-19 clinical course, she developed massive pulmonary thromboembolism resulting in secondary obstructive shock, which required pharmacological thrombolysis. At discharge, hormonal contraception was considered contraindicated, and the patient was released from our institution with continued oral anticoagulant therapy. COVID-19 infection, contraceptive hormone therapy, and overweight are known risk factors for the development of thromboembolic events. The impact of their concomitance has not been studied to date. From our experience, we discuss the impact these risk factors have when present together and invite others to report similar cases.
- 26 November 2021
- Published by MDPI AG in Clinics and Practice
- Vol. 11 (4) , 914-918
Open AccessHormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report
Coronavirus 19 disease (COVID-19) presents a highly variable clinical presentation and course, ranging from asymptomatic patients to rapidly progressive, fatal pneumonia. The known heterogeneous outcomes can affect both previously healthy patients and those with significant comorbidities, who develop clinical courses with possibly more multisystemic compromise. Likewise, the development of thrombotic phenomena during the acute course of the disease is associated with complications that worsen patient prognosis. We present a case report of a 45-year-old multiparous patient with a history of overweight and chronic use of oral hormonal contraception with low doses of levonorgestrel and estradiol as the only risk factors favoring the development of thrombotic events. During her outpatient COVID-19 clinical course, she developed massive pulmonary thromboembolism resulting in secondary obstructive shock, which required pharmacological thrombolysis. At discharge, hormonal contraception was considered contraindicated, and the patient was released from our institution with continued oral anticoagulant therapy. COVID-19 infection, contraceptive hormone therapy, and overweight are known risk factors for the development of thromboembolic events. The impact of their concomitance has not been studied to date. From our experience, we discuss the impact these risk factors have when present together and invite others to report similar cases.